PKIB
PKIB (cAMP-dependent protein kinase inhibitor beta, also known as PRKACN2) is a member of the PKI family and an extremely potent competitive inhibitor of cAMP-dependent protein kinase. It acts on the catalytic subunit of protein kinase A (PKA) within the PKA pathway. Browse Assay Genie's current range of PKIB research reagents below, or read on for the biology behind the target.
PKIB is an extremely potent competitive inhibitor of cAMP-dependent protein kinase activity. It interacts with the catalytic subunit of the enzyme after the cAMP-induced dissociation of its regulatory chains. In this way it acts on the free catalytic subunit, rather than on the inactive holoenzyme, and may play a role in the protein kinase A (PKA) pathway.
The PKIB gene encodes a member of the cAMP-dependent protein kinase inhibitor family, and the UniProt entry places the protein in the PKI family. Researchers working on this PKIB gene should note that alternatively spliced transcript variants encoding multiple isoforms have been observed. Orthologues are recognised in mouse and rat, both named Pkib, which allows the protein to be studied in common rodent models.
The gene has also been known as PRKACN2, and its earlier HGNC name was protein kinase (cAMP-dependent, catalytic) inhibitor beta. According to the NCBI Gene summary, overexpression of this gene may play a role in prostate cancer, which makes PKIB a point of interest for work on PKA signalling in disease. Studies of PKIB typically examine how a small inhibitory protein restrains the activity of the PKA catalytic subunit once cAMP has released it from its regulatory partners.
PKIB interacts with the PKA catalytic subunit after cAMP-induced release from the regulatory chains, making it relevant to studies of the PKA pathway.
As an extremely potent competitive inhibitor of cAMP-dependent protein kinase, PKIB is a model for how endogenous proteins restrain kinase activity.
NCBI Gene reports that overexpression of PKIB may play a role in prostate cancer, motivating investigation of its expression in tumour biology.
Alternatively spliced transcript variants encoding multiple isoforms have been observed for PKIB, supporting work on variant-specific expression and function.
PKIB is an extremely potent competitive inhibitor of cAMP-dependent protein kinase activity. It interacts with the catalytic subunit of the enzyme after cAMP-induced dissociation of the regulatory chains, and it may play a role in the protein kinase A (PKA) pathway.
PKIB is also known as PRKACN2, and its previous HGNC name was protein kinase (cAMP-dependent, catalytic) inhibitor beta. Alternatively spliced transcript variants encoding multiple isoforms have been observed for the gene, so check which isoform your work targets.
NCBI Gene states that overexpression of PKIB may play a role in prostate cancer. Mouse and rat both carry a Pkib ortholog. Check the datasheet of any product for its validated reactivity before using it with rodent samples.
Other PKI family members and components of the PKA pathway with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q9C010; product specifications from Assay Genie datasheets.